Comparison between epsilon-aminocaproic acid and tranexamic acid for total hip and knee arthroplasty: A meta-analysis

J Orthop Surg (Hong Kong). 2020 Sep-Dec;28(3):2309499020959158. doi: 10.1177/2309499020959158.

Abstract

Background: The aim was to compare the efficacy and safety of epsilon-aminocaproic acid (EACA) and tranexamic acid (TXA) in total hip arthroplasty (THA) and total knee arthroplasty (TKA).

Methods: Potential academic articles were identified from the Cochrane Library, Springer, PubMed, and ScienceDirect databases from inception to December 2019. Randomized controlled trials (RCTs) and non-RCTs involving EACA and TXA in THA or TKA were included. Pooled data were analyzed using RevMan 5.1.

Results: Three RCTs and three non-RCTs met the inclusion criteria. The present meta-analysis reveals that EACA is associated with significantly more blood loss than TXA. No significant differences were identified in terms of blood transfusion rate, transfusion units, hemoglobin (Hb) level at discharge, operation time, length of hospital stay, deep venous thrombosis (DVT), or 30-day readmission.

Conclusions: Compared with TXA, EACA led to more blood loss in patients undergoing THA or TKA. However, there was no significant difference in the blood transfusion rate, transfusion units, Hb level at discharge, operation time, length of hospital stay, DVT, or 30-day readmission between groups.

Keywords: aminocaproic acid; arthroplasty; blood loss; meta-analysis; tranexamic acid.

Publication types

  • Review

MeSH terms

  • Administration, Intravenous
  • Aminocaproic Acid / administration & dosage*
  • Antifibrinolytic Agents / administration & dosage
  • Arthroplasty, Replacement, Hip / methods*
  • Arthroplasty, Replacement, Knee / methods*
  • Blood Loss, Surgical / prevention & control*
  • Blood Transfusion
  • Humans
  • Length of Stay
  • Tranexamic Acid / administration & dosage*

Substances

  • Antifibrinolytic Agents
  • Tranexamic Acid
  • Aminocaproic Acid